In the latest bunch of recommendations from the European Medicines | Sanofi, Novo Nordisk, UCB and others received positive ...

Novavax (NVAX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...

Gilead Sciences (GILD) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to ...

The tool helps scientists understand how single-letter mutations and distant DNA regions influence gene activity, shaping ...

Euan Ashley's lab explores the intricate interactions of gene variants. Tiny "typos," or genetic mutations, can sneak into segments of DNA. Many of these are harmless, but some can cause health ...

Amicus and Rigel target rare diseases, but a pending BioMarin buyout and growing drug sales set up different upside paths for ...

The global liquid biopsy market is experiencing substantial growth, driven by increasing demand for non-invasive diagnostic technologies that detect molecular biomarkers using liquid samples, thus ...

Roivant Sciences (ROIV) is up ~110% in 6 months, but still has no product revenue. Read here for a detailed investment analysis.

This whitepaper explores the role of process analytical technology (PAT) in enhancing the efficiency of upstream ...

Sanofi's investment marks the entry of a strategic shareholder Support from existing investors Redmile Group, Artal, which is advised by Invus, and Sofinnova Partners Participation ...

Manufacturers that deliver specialized, turnkey solutions for critical processing stages are becoming strategic partners. The focus is on total cost of ownership, uptime reliability, and the ...

Key Highlights from the Quarter ACCENT Trial Success: The ACCENT trial, testing narmafotinib with gemcitabine and Abraxane®, continues to demonstrate ...